Exhibit 99.1

CAPITALIZATION AND INDEBTEDNESS

The following table sets forth our cash and cash equivalents, short term debt, including current portion of long term debt and our capitalization as of December 31, 2015 (prepared on the basis of International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”)).

	Dec. 31, 2015
	€ millions
(A) Cash and cash equivalents		9,148
(B) Short-term debt, and current portion of long-term debt		3,436
(C) Long-term debt		13,118
(D) Equity attributable to non-controlling interests		161
(E) Equity attributable to equity holders of Sanofi:
Share capital		2,611
Additional paid-in capital and retained earnings		52,010
Treasury shares		(298	)
Stock options and other share-based payments		2,814
Other items recognized directly in equity		912
Equity attributable to equity holders of Sanofi		58,049
(F) Capitalization (C+D+E)		71,328

As of March 15, 2016, the total aggregate amount of U.S. commercial paper outstanding was US$1.5 billion. No U.S. commercial paper was outstanding as of December 31, 2015.

As of March 10, 2016, following the repurchase and cancellation of shares in accordance with its share repurchase program, the value of the treasury shares of Sanofi amounted to €1,706 million.